Thryv Raises $30M Series B Led by InClin for Heart Failure Trial
SAN FRANCISCO – November 03, 2026 -- Thryv Therapeutics Inc. has raised a $30 million Series B financing led by InClin, Inc., a global contract research organization, to move its SGK1 inhibitor THRV-1268 into a Phase 2a heart failure study that opens for enrollment in early 2027.
The round follows completion of enrollment in the first efficacy cohort of the Wave II Phase 2/3 study of THRV-1268 in Long QT Syndrome. It also follows a favorable review of available Wave II data by the study's Independent Data Monitoring Committee (IDMC).
InClin brings clinical operations alongside capital
InClin, which operates in San Mateo, California and Sydney, Australia, joins as a strategic investor. In recent months Thryv has worked with the CRO to establish clinical operations in Australia, enabling initial patient enrollment in ASPIRE-HF early next year.